The KCa3.1 blocker TRAM34 reverses renal damage in a mouse model of established diabetic nephropathy
Open Access
- 9 February 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (2) , e0192800
Abstract
Despite optimal control of hyperglycaemia, hypertension, and dyslipidaemia, the number of patients with diabetic nephropathy (DN) continues to grow. Strategies to target various signaling pathways to prevent DN have been intensively investigated in animal models and many have been proved to be promising. However, targeting these pathways once kidney disease is established, remain unsatisfactory. The clinical scenario is that patients with diabetes mellitus often present with established kidney damage and need effective treatments to repair and reverse the kidney damage. In this studies, eNOS-/- mice were administered with streptozotocin to induce diabetes. At 24 weeks, at which time we have previously demonstrated albuminuria and pathological changes of diabetic nephropathy, mice were randomised to receive TRAM34 subcutaneously, a highly selective inhibitor of potassium channel KCa3.1 or DMSO (vehicle) for a further 14 weeks. Albuminuria was assessed, inflammatory markers (CD68, F4/80) and extracellular matrix deposition (type I collagen and fibronectin) in the kidneys were examined. The results clearly demonstrate that TRAM34 reduced albuminuria, decreased inflammatory markers and reversed extracellular matrix deposition in kidneys via inhibition of the TGF-β1 signaling pathway. These results indicate that KCa3.1 blockade effectively reverses established diabetic nephropathy in this rodent model and provides a basis for progressing to human studies.Keywords
Funding Information
- Juvenile Diabetes Research Foundation International (2-SRA-2014-258-Q-R)
- National Health and Medical Research Council (APP1110560)
This publication has 42 references indexed in Scilit:
- Extracellular Matrix Degradation and Remodeling in Development and DiseaseCold Spring Harbor Perspectives in Biology, 2011
- Renal fibrosis: novel insights into mechanisms and therapeutic targetsNature Reviews Nephrology, 2010
- Therapeutic potential of KCa3.1 blockers: recent advances and promising trendsExpert Review of Clinical Pharmacology, 2010
- Vascular KCa-channels as therapeutic targets in hypertension and restenosis diseaseExpert Opinion on Therapeutic Targets, 2010
- TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Therapeutic Intervention in Diabetic NephropathyAmerican Journal of Nephrology, 2009
- Renal fibrosis is attenuated by targeted disruption of K Ca 3.1 potassium channelsProceedings of the National Academy of Sciences, 2009
- The K+ channels KCa3.1 and Kv1.3 as novel targets for asthma therapyBritish Journal of Pharmacology, 2009
- Role of Krüppel-like factor 6 in transforming growth factor-β1-induced epithelial-mesenchymal transition of proximal tubule cellsAmerican Journal of Physiology-Renal Physiology, 2008
- Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemiaBlood, 2008
- ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD miceBlood, 2003